SLU Researcher Finds Help for Alzheimer's-Associated Agitation with New FDA-Approved Treatment
ST. LOUIS – A Saint Louis University researcher was instrumental in developing the first and only Food and Drug Administration (FDA) approved treatment for agitation associated with Alzheimer’s dementia.
In a paper published in JAMA Neurology, senior author and the inaugural Henry & Amelia Nasrallah Endowed Professor and Director of Geriatric Psychiatry at Saint Louis University George T. Grossberg, M.D., and colleagues shared the results of a national clinical trial. They discovered that REXULTI, also called brexpiprazole, significantly reduced agitation in patients with Alzheimer’s disease and was well tolerated with few side effects.
George Grossberg, M.D. Photo by Sarah Conroy.
Earlier this year, brexpiprazole became the first FDA-approved treatment of agitation-associated Alzheimer’s dementia.
Of the 6.7 million people 65 and older in the US with Alzheimer’s dementia, multiple studies show that about half or more develop agitation.
Agitation associated with Alzheimer’s dementia may include activities like restlessness or more aggressive behavior, like screaming, destroying objects or fighting. Frequent and severe behavioral symptoms can be extremely distressing to the person with Alzheimer’s disease, as well as their families and caregivers.
Antipsychotic drugs are commonly prescribed “off-label” to treat symptoms like aggression and agitation. While these antipsychotics seem to show a modest benefit in treating aggression in the short term, they have adverse effects and other health risks that limit their use over more extended periods.
“When patients with Alzheimer’s dementia develop agitation symptoms, they can become increasingly difficult to manage,” said Grossberg, who is also director of geriatric psychiatry at SLU. “I’m encouraged by the findings of this study which show that brexpiprazole is an effective and well-tolerated medication that can treat the often-debilitating symptoms of agitation associated with dementia due to Alzheimer’s disease.”
In the multicenter Phase 3 clinical trial, researchers evaluated the efficacy and safety of brexpiprazole, a medication used for the treatment of major depressive disorder and schizophrenia, for patients with agitation associated with Alzheimer’s.
The clinical trial was a 12-week, double-blind, placebo-controlled, fixed-dose, parallel-arm trial that enrolled 345 participants at 123 clinical trial sites in Europe and the United States.
Investigators enrolled participants between the ages of 55 to 90 with a diagnosis of probable Alzheimer’s disease and clinically significant symptoms of agitation who lived in a care facility or community-based setting.
Participants were randomly assigned to receive the study drug or a placebo. To participate in the clinical trial, participants had to be stable and have a caregiver who could comply with the study procedures.
“It can be extremely challenging to care for patients with Alzheimer’s disease,” said Grossberg. “Having new medications to help patients who are suffering will enormously benefit patients, healthcare providers, and those caring for their loved ones.”
The clinical trial was supported by Otsuka Pharmaceutical Development & Commercialization and H. Lundbeck.
For more information about the trial, visit ClinicalTrials.gov. The study’s Clinical Trials Identifier is NCT03548584.
Latest Newslink
- Frequent Heartburn May Signal Risk for Alcohol Use Disorder, SLU Study FindsA new study from Saint Louis University reveals that individuals with frequent heartburn—clinically known as gastroesophageal reflux disease (GERD)—have a higher chance of being diagnosed with alcohol use disorder within two years. Researchers are urging primary care providers to screen GERD patients for alcohol misuse during routine visits.
- St. Louis Literary Award Events to Kick Off with Screening of “The Namesake,” Talk with Director Mira NairSaint Louis University will welcome Pulitzer Prize-winning author Jhumpa Lahiri to campus in 2026 to receive the St. Louis Literary Award. Literary Award programming kicks off the week of Oct. 27 with a showing of the film "The Namesake" and a discussion with director Mira Nair.
- SLU Hispanic Studies Professor Named Distinguished Visiting Professor in the Humanities at East Carolina UniversityAmy E. Wright, Ph.D., professor of Hispanic Studies at Saint Louis University, has been named the David Julian and Virginia Suther Whichard Distinguished Professor in the Humanities at East Carolina University. She will hold the visiting Whichard professorship in ECU’s Thomas Harriot College of Arts and Sciences for two years before returning to SLU.
- SLU, Maryville Team Up with Women in Cybersecurity to Close the Cyber Talent GapStudents from the Saint Louis University and Maryville University Women in Cybersecurity chapters are teaming up to address one of the nation's most critical challenges: the shortage of skilled professionals trained to combat escalating cybersecurity threats.
- SLU's Emerson Leadership Institute to Kick Off Speaker Series with Barry-Wehmiller's Bob ChapmanSaint Louis University’s Emerson Leadership Institute will host Bob Chapman, chairman of Barry-Wehmiller, as part of its Leadership Speaker Series on Monday, Nov. 3. The free event will include a fireside chat on dignity-based leadership with Jackson Nickerson, Ph.D., Edward Jones Dean of the Richard A. Chaifetz School of Business at SLU.
- SLU's Flying Billikens to Host Regional Event for National Intercollegiate Flying CompetitionThe Flying Billikens from the Oliver L. Parks Department of Aviation Science will host the 2025 National Intercollegiate Flying Association Competition's Region VI and VIII SAFECON event Oct. 13-18 at the St. Louis Downtown Airport.
